Oxazoline Composition for Infant Cradle Cap and Malassezia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for conditions caused by Malassezia yeasts, such as seborrheic dermatitis and cradle cap, often have adverse side effects like skin atrophy and contact dermatitis, and are not suitable for infants and children.
Innovation Solution
A composition comprising oxazoline (e.g., OX100) with malic acid diester, vegetable oil oleodistillate, and arabinogalactan inhibits Malassezia yeast growth, providing anti-inflammatory and keratolytic effects while being safe for topical use in infants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If corticosteroids are used to treat seborrheic dermatitis, then inflammation is reduced, but skin atrophy and other side effects occur
Solution Approach 1:
The patent uses oxazoline compounds as intermediary substances that provide anti-inflammatory effects without the harmful side effects of corticosteroids. The oxazoline acts as a mediator between the need for inflammation reduction and the avoidance of skin atrophy, offering a safer alternative for treating seborrheic dermatitis in infants and children.
Solution Approach 2:
The patent employs oxazoline compounds as a replacement for corticosteroids, providing a shorter-acting but safer alternative that does not accumulate harmful effects with prolonged use. This approach allows for effective treatment while avoiding the long-term damage associated with corticosteroid therapy.
2Object-affected harmful factors
If antifungal drugs are used to treat Malassezia infections, then yeast growth is inhibited, but contact dermatitis occurs
Solution Approach 1:
The oxazoline compounds serve as intermediary agents that inhibit Malassezia yeast growth without causing contact dermatitis. These compounds provide an alternative mechanism for antifungal action that spares the skin from the irritating side effects of conventional antifungal drugs.
Solution Approach 2:
The patent changes the chemical parameters of the antifungal agent by using oxazoline compounds with different molecular structures and mechanisms of action compared to conventional antifungals. This parameter change results in a substance that is effective against Malassezia but does not provoke contact dermatitis.
3Object-affected harmful factors
If conventional treatments are used for cradle cap, then symptoms are managed, but the treatments are not suitable for infants and children
Solution Approach 1:
The patent applies oxazoline compounds specifically formulated for pediatric use, creating a treatment with local quality suited for infants and children. The composition is tailored to be gentle on delicate infant skin while maintaining effectiveness against cradle cap, making it adaptable to the specific needs of this patient population.
Solution Approach 2:
The patent modifies the treatment parameters by using oxazoline compounds with appropriate concentration ranges and formulations specifically designed for infant and children's skin. This creates a treatment regimen that is both effective and safe for pediatric patients, addressing the adaptability issue with conventional treatments.
Data Source
AI summary
The present invention relates to a composition comprising at least one oxazoline, such as OX100, for inhibiting the growth of Malassezia yeasts and/or for preventing and/or treating conditions caused by Malassezia yeasts, seborrheic dermatitis, cradle cap, Malassezia folliculitis, dandruff, Pityriasis versicolor or Pityriasis capitis. The present invention also relates to a composition comprising at least one oxazoline such as OX100, at least one compound such as malic acid diester and a vegetable oil oleodistillate and/or arabinogalactan, and to the use of same for preventing and/or treating, in particular, affections caused by Malassezia yeasts, seborrheic dermatitis, cradle cap, Malassezia folliculitis, dandruff, Pityriasis versicolor or Pityriasis capitis.